Ondine Biomedical Inc. (LON: OBI) announces publication of the first randomized, placebo-controlled, single-blind clinical study of Steriwave nasal photodisinfection in 75 predominantly vaccinated COVID-19 patients.

The study, published in Frontiers in Cellular and Infection Microbiology,[1] met its primary endpoint, with a highly significant decrease in viral infectivity recorded as early as two days after treatment (p

(C) 2023 Electronic News Publishing, source ENP Newswire